All about Cabergoline

Cabergoline was developed in the 1980s. The most well-known brand name is Dostinex, originally produced by Pharmacia and later by Pfizer, and marketed in the United States and many other countries.

For a number of years, Dostinex was the primary branded cabergoline product in the U.S. After patent expiration, several generic versions were approved by the FDA between 2005 and 2007, including products from Barr, Ivax, and Par Pharmaceutical.

Chemical Structure and Mechanism of Action

Cabergoline is an ergoline (ergot-derived) dopamine agonist.

Chemically, it is a synthetic derivative of ergoline. In scientific literature, cabergoline is described as a long-acting dopamine receptor agonist rather than by its full chemical name, which is rarely used in clinical contexts.

Primary Mechanism

The main mechanism of action of cabergoline is activation of dopamine D2 receptors located on pituitary lactotroph cells. Stimulation of these receptors leads to a decrease in prolactin secretion.

Additional Receptor Activity

Cabergoline also shows affinity for several other receptors, including:

Dopamine receptors: D3, D4;
Serotonin receptors: 5-HT1A, 5-HT2A, 5-HT2B, 5-HT2C;
Adrenergic receptors: α2B.

Some of these interactions may contribute to side effects rather than therapeutic effects. In particular, activity at 5-HT2B receptors has been associated with cardiac valve pathology during long-term high-dose use.

Effects

Effects Associated With Lowered Prolactin in Men

When prolactin levels are elevated, reducing them may improve certain aspects of well-being and sexual function.

Low prolactin levels, especially when combined with normal or high testosterone levels, are often associated with:

Improved libido and sexual performance;
Reduced refractory period between sexual acts;
Improved subjective sense of motivation and confidence.

Claims that low prolactin directly determines personality traits (such as polygamous behavior or resistance to social influence) are speculative and not supported by clinical endocrinology.

There is no reliable evidence that lowering prolactin causes enlargement of the penis or testicles in adult men. Improvements reported in this area are more likely related to changes in libido, erectile function, or perception rather than anatomical growth.

Side Effects

In a study involving patients with Parkinson’s disease receiving long-term, relatively high doses of cabergoline, the following side effects were reported.

Digestive System (most common)

Nausea;
Constipation;
Dry mouth;
Dyspepsia.

Nervous System

Insomnia;
Dizziness;
Depressed mood;
Altered or confused mental state.

Cardiovascular System

Drop in blood pressure (orthostatic hypotension);
Peripheral edema;
Heart rhythm disturbances;
Cardiac valve damage (with long-term high-dose use);
Pericarditis.

Immune System

Rare hypersensitivity reactions;
Skin rashes.

Hematopoietic System

Infrequent cases of erythromelalgia.

Respiratory System

Shortness of breath (relatively common at higher doses);
Rarely: pleural effusion, pulmonary fibrosis, nasal bleeding.

At low doses, side effects are less common. The most frequently reported issues at endocrine-level dosing include reduced appetite, fatigue, and low mood. Psychiatric effects such as impulse-control problems may occur in susceptible individuals.

Dosages and Uses

Typical Dosage

Single dose: 0.25 mg.

Frequency of Use

Every 4 days (commonly used);
Every 2 days (more intensive use).

To suppress prolactin, cabergoline is commonly taken at 0.5 mg per week, divided into one or more doses. Depending on prolactin levels and individual response, the dose may be increased to 1 mg per week. In rare medical cases, higher doses have been used under strict supervision.

Therapy duration is typically 4–6 weeks, followed by reassessment.

Cycles (Courses)

Practical experience suggests that cabergoline use for prolactin control is often structured as follows.

During Progestin-Based Steroid Use

(e.g., Deca Durabolin or Trenbolone)

0.25 mg is taken every 7–21 days, beginning around the 3rd or 4th week of the course, when progestin activity becomes more pronounced.
Dose and frequency are adjusted based on prolactin blood tests, as individual response varies.

If prolactin levels exceed the acceptable range:

Frequency may increase to 0.25 mg every 4 days;
Follow-up prolactin testing is typically performed after two doses, with further adjustments as needed.

Cabergoline is generally taken with food. Time of day is not critical. Use is recommended only under medical supervision, especially when combined with other hormonal agents.

Use in Bodybuilding Contexts

In bodybuilding, cabergoline is most often used during courses involving nandrolone or trenbolone.

Common Practice Patterns

0.25 mg every 4 days if prolactin is elevated;
If prolactin remains high, 0.25 mg every 2 days may be used temporarily;
Once prolactin normalizes, users often return to the less frequent schedule.

During such courses, cabergoline may also reduce fluid retention associated with elevated prolactin. The most commonly used pharmaceutical form is Dostinex or its generics.

Some users also report using cabergoline during non-progestin cycles to subjectively improve well-being. In these cases, doses are typically lower, such as 0.5 mg once every 10 days.

Athletes occasionally use cabergoline outside of anabolic steroid use. In such cases, doses are usually minimal, and effects are largely limited to prolactin suppression rather than direct performance enhancement.

Common Cabergoline Stacks (Contextual, Not Prescriptive)

These are illustrative examples of how cabergoline is commonly discussed alongside other compounds. They are not instructions and assume medical oversight and lab monitoring.

Cabergoline + Fat-Loss–Oriented Compounds

Stack Goal	Typical Context	Cabergoline Role	Notes
Appetite control	Calorie-restricted phases	Prolactin suppression	Dopamine tone may blunt appetite in some users;
Diet fatigue reduction	Extended cuts	Dopamine support	Effects vary widely;
Water retention management	Hormonal fluctuations	Indirect	Not a diuretic; effects are secondary.

Key point: Cabergoline does not burn fat. Any weight-loss benefit is indirect.

Cabergoline in Progestin-Heavy Cycles

Context	Why Cabergoline Is Added	Typical Range Seen
Nandrolone-based cycles	Prolactin elevation risk	Low, infrequent dosing;
Trenbolone-based cycles	Libido / prolactin management	Adjusted based on labs;

Reality check: If prolactin is normal, cabergoline adds little and increases risk.

PCT and Cabergoline: What People Get Wrong

Cabergoline is not a PCT drug.
It does not restart the HPTA. It does not replace SERMs.

Where it sometimes shows up post-cycle:

Persistently elevated prolactin after suppressive compounds;
Libido or erectile dysfunction clearly linked to prolactin, not testosterone;
Short, monitored use to normalize labs before recovery continues.

Bad idea: running cabergoline “just in case” during PCT. That’s how people crash dopamine and feel flat for weeks. You need Nolvadex, not Caber, for PCT.

Cabergoline vs Similar Compounds (Same World, Different Tools)

Cabergoline vs Bromocriptine

Feature	Cabergoline	Bromocriptine
Half-life	Very long	Short
Dosing frequency	Infrequent	Daily
Side effects	Lower nausea overall	Higher GI issues
Clinical preference	Modern standard	Older option

Cabergoline largely replaced bromocriptine for a reason.

Cabergoline vs Pramipexole / Ropinirole

Aspect	Cabergoline	Dopamine Agonists (PD-type)
Prolactin suppression	Strong	Minimal
Appetite effects	Indirect	Sometimes strong
Impulse-control risk	Moderate	Higher
Use case	Endocrine	Neurological

These are not interchangeable, despite forum myths.

Cabergoline and Weight Loss: The Honest Framing

Cabergoline may:

Reduce prolactin-related water retention;
Improve diet adherence in some individuals via dopamine signaling;
Normalize libido and motivation disrupted by hormonal imbalance.

Cabergoline will not:

Replace calorie control;
Act as a stimulant or thermogenic;
Produce reliable fat loss on its own.

If weight drops fast after starting cabergoline, it’s usually water, appetite change, or behavior, not fat oxidation.

Final Reality Check

Cabergoline is a scalpel, not a hammer.
Used with labs, purpose, and restraint, it can solve very specific problems.
Used casually, it creates new ones — especially mood, motivation, and cardiovascular issues.

References

Randomized Pilot Study of Cabergoline, a Dopamine Receptor Agonist: Effects on Body Weight and Glucose Tolerance in Obese Adults https://pmc.ncbi.nlm.nih.gov/articles/PMC3290696/
Cabergoline counteracts adipose and skeletal muscle lipid accumulation: A novel therapeutic approach to obesity? https://www.sciencedirect.com/science/article/pii/S0753332225004378
Effect of Cabergoline on weight and glucose metabolism in patients with acromegaly https://link.springer.com/article/10.1007/s40618-024-02396-1
SAT-073 Exploring Metabolic Changes With Cabergoline Therapy In Prolactinoma: A Retrospective Analysis https://academic.oup.com/jes/article/9/Supplement_1/bvaf149.1555/8298284
Cabergoline prevents weight gain in patients evaluated for hyperprolactinaemia https://www.endocrine-abstracts.org/ea/0025/ea0025p130